CAPRISA 018

Status

Ongoing

Phase

Objective

The proposed CAPRISA 018 trial aims to primarily assess the safety, acceptability and pharmacokinetics (PK) of the TAF implant, and secondarily to obtain a preliminary estimate of efficacy for HIV prevention in young South African women

Prevention Option(s)

PrEP

Arms and Assigned Interventions

Description

Tenofovir Alafenamide (TAF) Implant

Products

tenofovir

Official Code

CAPRISA 018

Trial Sponsors

Centre for the Aids Programme of Research in South Africa; Stichting Amsterdam Institute for Global Health and Development; Université Jean Monnet, Saint-Etienne

Product Developers

CAPRISA/ Oak Crest

January 2017

December 2022

Population

Women

You are here

CAPRISA 018